Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potential For Califf’s Second US FDA Commissioner Term Surprises, Excites Stakeholders

Executive Summary

Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.

You may also be interested in...



Clinical Trial Disclosure: Only ‘Tiny Fraction’ Of Thousands Of Unreported Results Cited By US FDA

Yale researchers call on FDA to send more pre-notices of noncompliance to those who have not reported trial results. Of 58 pre-notices in last eight years, 56% went to pharma industry and none went to federal agencies. Commissioner-in-waiting Califf is expected to focus on trial reporting.

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

What Might Have Been: US FDA’s Woodcock Testifies In Senate

Acting US FDA Commissioner Woodcock’s latest appearance before the Senate Health Committee shows once again that she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel